Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mavatrep. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 known ✓ | Q8NER1 | 20/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mavatrep SCHEMBL1800948 | 1.00 | TRPV1 (0.84) | TRPV1 | |
| Mavatrep SCHEMBL1796599 | 0.99 | TRPV1 (0.85) | TRPV1 | |
| Mavatrep SCHEMBL1797450 | 0.99 | TRPV1 (0.85) | TRPV1 | |
| Mavatrep SCHEMBL1796595 | 0.99 | TRPV1 (0.85) | TRPV1 | |
| Mavatrep SCHEMBL29636978 | 0.99 | TRPV1 (0.85) | TRPV1 | |
| Mavatrep SCHEMBL1799282 | 0.98 | TRPV1 (0.84) | TRPV1 | |
| Mavatrep SCHEMBL1799278 | 0.98 | TRPV1 (0.84) | TRPV1 | |
| SCHEMBL1797832 | 0.91 | TRPV1 (0.72) | TRPV1 | |
| SCHEMBL1797830 | 0.91 | TRPV1 (0.72) | TRPV1 | |
| SCHEMBL1801774 | 0.90 | TRPV1 (0.70) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190344-A1 | BENZIMIDAZOLE MODULATORS OF VR1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-08-04 | — | — | US | disclosed |
| US-20110190364-A1 | BENZIMIDAZOLE MODULATORS OF VR1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-08-04 | — | — | US | disclosed |
| US-7951829-B2 | Benzimidazole modulators of VR1 | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-31 | — | — | US | disclosed |
| EP-2021330-B1 | BENZIMIDAZOLE MODULATORS OF VR1 | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-22 | — | — | EP | disclosed |
| US-20070259936-A1 | Benzimidazole Modulators of VR1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190364-A1 | BENZIMIDAZOLE MODULATORS OF VR1 | VRK1, VRK2, VIL1 | TRPV1 29/4885 |
| US-20070259936-A1 | Benzimidazole Modulators of VR1 | VRK1, VRK2, VIL1 | TRPV1 29/4885 |
| US-20110190344-A1 | BENZIMIDAZOLE MODULATORS OF VR1 | VRK1, VRK2, VIL1 | TRPV1 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.